Drug
Brexanolone
Brexanolone: highest development phase Post-Market, developed by Sage Therapeutics, Supernus Pharmaceuticals. 7 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sage Therapeutics, Supernus Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brexanolone NCT04273191 | Post-Market | Postpartum Depression |
| Brexanolone NCT03665038 | Phase 3 | Post Partum Depression |
| Brexanolone NCT04537806 | Phase 3 | Acute Respiratory Distress Syndrome |
| Brexanolone NCT06580444 | Phase 2 | Alcohol Use Disorder (AUD) |
| Brexanolone NCT05645432 | Phase 2 | Tinnitus |
| Brexanolone NCT05223829 | Phase 1 | PTSD |
| Brexanolone NCT05314153 | Phase 1 | Postpartum Psychosis |
Latest
No recent events.
Follow Brexanolone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.